Abstract. To 
Abstract. To characterize dopaminergic influences on pancreatic islet D cell function and its potential interaction with islet A and B cell function, the effect of dopamine (0.5\p=n-\100\g=m\m) on immunoreactive somatostatin (IRS), insulin (IRI), and glucagon (IRG) release from rat islets incubated in vitro was studied. Dopamine significantly suppressed the release of IRS (P< 0.001) and IRI (P < 0.001) and augmented IRG release (P < 0.001). Maximum suppression of IRS and IRI release was evident at 20 \g=m\m dopamine with half-maximal suppression occurring at 0.5\p=n-\1\g=m\m.Maximal stimulation of IRG release was observed at 100 \g=m\m dopamine with a halfmaximal response occurring at 5\p=n-\10 \g=m\m.Suppression of IRS secretion by dopamine (20 \g=m\m) was completely reversed by the dopaminergic antagonists haloperidol (5 \g=m\m) and pimozide (5 \g=m\m), but was only partially reversed by the alpha adrenergic antagonist phentolamine (2 \g=m\m), and was further suppressed by the beta adrenergic antagonist propranolol (2 \g=m\m Histochemical studies indicate that endocrine cells of pancreatic islets contain dopamine (Cegrell 1968 ). The observations that this catecholamine inhibits insulin secretion (Feldman et al. , 1972 ; Lebovitz & Feldman 1973; (IRI) were measured by radioimmunoassay as described pre¬ viously . Rat 
Results
Effect ofdopamine on somatostatin, insulin and glucagon secretion: dose-response relationship (Fig. 1) The effects of dopamine (0.5-20 um) on 1RS, IRI, and IRG secretion are given in Fig. 1 Effect ofdopaminergic antagonists on norepinephrine-incuded changes in somatostatin, insulin, and glucagon secretion (Table 2) To determine whether the reversal of dopamine suppression of 1RS release by haloperidol and pimozide could have been due to alpha adrenergic antagonistic actions of these agents, the effects of haloperidol and pimozide on the suppression of 1RS secretion induced by an alpha adrenergic agonist, norepinephrine (1 um), were studied. (Lorenzi et al. 1977 (Lorenzi et al. , 1979 George & Bailey 1978) but not all (George & Rayfield 1974) (Caron et al. 1978; Robinson & Sulser 1976) . Although halo¬ peridol has weak alpha adrenergic antgonist acti¬ vity, pimozide at the concentrations used in the present study would be expected to be devoid of such actions (Ennis & Cox 1980) . In other studies, dopamine has been reported to increase somatosta¬ tin release from rat hypothalamus in vivo (Chihara et al. 1979) , rat cerebral cortex in vitro (Bennett et of a stimulatory beta adrenergic effect or a combi¬ nation of both processes. Preliminary evidence from our laboratory using epinephrine in the pre¬ sence of specific adrenergic antagonists (Itoh et al. 1980a) indicates beta adrenergic stimulation aug¬ ments while alpha adrenergic stimulation decreases somatostatin release from isolated rat islets.
Exogenous somatostatin is a potent inhibitor of insulin and glucagon secretion (Gerich et al. 1975 
